直接抗病毒药物治疗晚期慢性肾脏病丙型肝炎的系统综述
为支持2022年KDIGO指南更新,该系统综述检索截至2022年2月1日的文献,纳入106项研究,评估直接抗病毒药物在CKD G4-G5ND、G5D及肾移植受者中的疗效与安全性。多数方案SVR12≥93%,严重不良事件风险低,肾移植受者中治疗与未治疗相比死亡风险显著降低(汇总OR 0.16,95%CI 0.04-0.61)。
要点
- 在CKD G4-G5ND、G5D及肾移植受者中,多数DAA方案SVR12≥93%。
- 严重不良事件风险低(多数0%,最高2.9%),因不良事件停药风险低(多数0%-5%)。
- 肾移植受者中,DAA治疗后死亡风险低于未治疗(汇总OR 0.16,95%CI 0.04-0.61)。
核心结论
- 联合DAA方案在晚期CKD、透析及肾移植患者中安全且高效。
研究设计与样本
- 系统综述检索PubMed、Embase、Cochrane、CINAHL和ClinicalTrials.gov至2022年2月1日,并检索2019至2021年会议资料。
- 纳入106项研究,其中22项报告CKD G4-G5ND、69项报告G5D、29项报告肾移植受者。
- 采用最大似然法荟萃分析,并按GRADE评估证据确定性。
主要发现
- 各人群中多数DAA方案SVR12≥93%。
- 严重不良事件风险普遍较低(多数0%,最高2.9%),因不良事件停药风险低(多数0%-5%)。
- 肾移植受者中3项未校正观察性研究显示,DAA治疗后死亡风险显著低于未治疗(汇总OR 0.16,95%CI 0.04-0.61)。
局限性
- 证据质量普遍较低。
- 肾移植受者中死亡风险比较来自3项未校正观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Direct-acting antivirals (DAAs) have improved treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD). To facilitate the 2022 update of the Kidney Disease: Improving Global Outcomes (KDIGO) guideline for CKD patients with HCV, we systematically reviewed DAA regimens in patients with CKD stages G4 and G5 nondialysis (G4-G5ND), CKD stage G5 on dialysis (G5D), and kidney transplant recipients (KTRs). METHODS: We conducted a systematic review by searching PubMed, Embase, Cochrane, CINAHL, and ClinicalTrials.gov through February 1, 2022, and conferences from 2019 to 2021. Studies of HCV-infected patients with CKD G4-G5ND, G5D, and KTRs treated with specified DAA regimens were included. Outcomes included death at 6 months or later, sustained virologic response at 12 weeks (SVR12), serious adverse events (SAEs) attributed to DAA, and treatment discontinuation because of adverse events. Maximum likelihood meta-analyses were determined; certainty of evidence was assessed per GRADE (Grading of Recommendations Assessment, Development, and Evaluation). RESULTS: We identified 106 eligible studies (22 reported on CKD G4-G5ND, 69 on CKD G5D, and 29 on KTRs). In each population, the majority of DAA regimens achieved SVR12 ≥ 93%. We found generally low quality of evidence of low risk of SAEs (mostly 0%, up to 2.9%) and low risk of discontinuation because of adverse events (mostly 0%-5%). Across 3 unadjusted observational studies in KTRs, the risk of death after DAA treatment was substantially lower than without treatment (summary odds ratio, 0.16; 95% CI, 0.04-0.61). CONCLUSION: Combination DAA regimens are safe and highly effective in patients with advanced CKD, on dialysis, and with kidney transplants.
引用
- Balk EM, Adam GP, Jadoul M, et al. A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD. Kidney Int Rep. 2022. PMID: 36815114. doi:10.1016/j.ekir.2022.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。